Last Price$272.70.1%
Market Cap$19.4B
12.0%
Peers median - 3.1%
15.9%
Peers median - 14.8%
6.9%
Peers median - 37.2%
29.7%
Peers median - 11.2%
Competing with PODD
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare PODD Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Insulet CorporationPODD
9.7x
30.0%
4,364.6%
12.2%
Median Peer Set
5.4x
4.1%
72.0%
12.4%
Abbott LaboratoriesABT
5.9x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
3.2x
3.4%
26.0%
11.5%
Boston Scientific CorporationBSX
9.9x
17.6%
16.7%
11.1%
DexCom, Inc.DXCM
8.6x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.8x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
118.1%
(3.9%)
STERIS plcSTE
4.1x
3.6%
257.9%
7.4%
Stryker CorporationSYK
7.0x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
4.8x
6.5%
253.2%
13.8%
Compare PODD Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Insulet Corporation (PODD) revenue growth compare to peers and the industry?
Insulet Corporation (PODD) revenue growth is 12.0%, compared to the peers' median of 3.1%.
2. How does Insulet Corporation (PODD) Free Cash Flow (FCF) margin compare to peers and the industry?
Insulet Corporation (PODD) FCF margin is 15.9%, compared to the peers' median of 14.8%.
3. How does Insulet Corporation (PODD) Total Debt to Equity ratio compare to peers and the industry?
Insulet Corporation (PODD) Total Debt to Equity ratio is 6.9%, compared to the peers' median of 37.2%.
4. How does Insulet Corporation (PODD) ROIC (Return on Invested Capital) compare to peers and the industry?
Insulet Corporation (PODD) ROIC is 29.7%, compared to the peers' median of 11.2%.